Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

Clinical and Experimental Allergy

Volumn 34, Issue 4, 2004, Pages 632-638

  Holgate, S T ^a   Chuchalin, A G ^b   Hebert J ^c   Lotvall J ^d   Persson, G B ^e   Chung, K F ^f   Bousquet, J ^g   Kerstjens, H A ^h   Fox, H ⁱ   Thirlwell, J ⁱ   Della Cioppa, G ⁱ  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b Research Institute of Pulmonology   (Russian Federation)

^c CRAAQ   (Canada)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Proevningsenheten   (Sweden)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g HÔPITAL ARNAUD DE VILLENEUVE   (France)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Allergic asthma; Fluticasone; IgE; Monoclonal antibody; Omalizumab; Quality of life

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE; OMALIZUMAB;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN BRUISING; SKIN MANIFESTATION; TREATMENT OUTCOME; URTICARIA;

ADOLESCENT; ADULT; AGED; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 11144356805     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.1916.x     Document Type: Article

References (26)

1. Serra-Battles J, Plaza V, Morejón E, Comella A, Brugués J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12:1322-6.
2. Chung KF, Godard P, Ädelroth E et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. Eur Respir J 1999; 13:1198-208.
3. Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999; 402 (Suppl.):B12-7.
4. Sears MR, Herbison GP, Holdaway MD, Hewitt CJ, Flannery EM, Silva PA. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. Clin Exp Allergy 1989; 19:419-24.
5. Holgate ST. The epidemic of allergy and asthma. Nature 1999; 402 (Suppl.):B2-4.
6. Presta LG, Lahr SJ, Shields RL et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151:2623-32.
7. Henry AJ, McDonnell JM, Ghirlando R, Sutton BJ, Gould HF. Conformation of the isolated c3 domain of IgE and its complex with the high affinity receptor FcεR1. Biochemistry 2000; 39:7406-13.
8. Shields RL, Whether WR, Zioncheck K et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995; 107:308-12.
9. Liu J, Lester P, Builder S, Shire SJ. Characterisation of complex formation by humanised anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995; 34:10474-82.
10. Corne J, Djukanović R, Thomas L et al. The effect of intravenous administration of a chimaeric anti-IgE antibody on serum IgE levels in atopic subjects - efficacy, safety and pharmacokinetics. J Clin Invest 1997; 99:879-87.
11. Fahy JV, Fleming HE, Wong HH et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828-34.
12. Boulet LP, Chapman KR, Côté J et al. Inhibitory effects of an anti-IgE antibody E25 allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155:1835-40.
13. Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996; 279:1000-8.
14. Boushey HA Jr. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 2001; 108 (2 Part 2): S77-83.
15. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108 (2 Part 1):184-90.
16. Solèr M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-61.
17. Milgrom H, Berger W, Nayak A et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108 (2):e36. Full text available at www.pediatrics.org/cgi/content/full/108/2/e36.
18. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993; 147:832-8.
19. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47:81-7.
20. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomized trials. BMJ 1998; 316:690-3.
21. Agresti A. An introduction to categorical data analysis, version 6. New York: Wiley, 1996.
22. SAS/STAT SAS/STAT user's guide, Vol. 1-2, Version 6, 1st edn. SAS Institute, Cary, NC, 1990.
23. Milgrom H, Fick RB Jr, Su JQ et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999; 341:1966-73.
24. Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard P. Rhinosinusitis in severe asthma. J Allergy Clin Immunol 2001; 107:73-80.
25. Casale TB, Condemi J, LaForce C et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis. JAMA 2001; 286: 2956-67.
26. Ädelroth E, Rak S, Haahtela T et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106:253-9.